Effect of liraglutide on body weight and microvascular function in non-diabetic overweight women with coronary microvascular dysfunction.

Suhrs HE, Raft KF, Bové K, Madsbad S, Holst JJ, Zander M, Prescott E

International journal of cardiology2 Jan 2019Cited by 16 (Europe PMC)

PMID30773266DOI10.1016/j.ijcard.2018.12.005PepBankPUB-30773266

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, coronary flow velocity reserve did not change with liraglutide (mean change 0.07).
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide did not improve blood flow reserve in the heart.
Peptide
Liraglutide
Outcome
No significant changeCoronary flow velocity reserve (CFVR) change
Study
n = 29
Comparator
Control period without liraglutide
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Measurements
CFVR baseline median
2.3
baseline
CFVR mean change
0.07
after liraglutide
Source sentences
Summary
Baseline median CFVR was 2.30 (IQR 1.91;2.51) and remained unchanged after liraglutide treatment (mean change 0.07 (95%CI: -0.07;0.21)).
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were change in CFVR and change in angina symptoms measured by the Seattle Angina Questionnaire (SAQ)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326603
02HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, liraglutide had no effect on angina symptoms measured by the Seattle Angina Questionnaire.
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide did not ease chest pain symptoms.
Peptide
Liraglutide
Outcome
No significant changeAngina symptoms (Seattle Angina Questionnaire)
Study
n = 29
Comparator
Control period without liraglutide
Analysis
Primary
Outcome group
Heart function · Cardiovascular
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no effects on symptoms measured by SAQ
3 context sentences(design, population, supporting numbers)
Summary · context
Primary outcomes were change in CFVR and change in angina symptoms measured by the Seattle Angina Questionnaire (SAQ)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326604
03HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, liraglutide led to a mean weight loss of 6.03 kg.
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide led to weight loss.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n = 29
Comparator
Control period without liraglutide
Outcome group
Body weight · Metabolic and weight
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Measurements
Weight loss
6.03 kg
liraglutide
Source sentences
Summary
Liraglutide treatment led to a significant weight loss (mean 6.03 kg (95%CI: 5.22;6.84)) and decrease in systolic blood pressure (mean 10.95 mm Hg (95%CI: 4.60;17.30)).
2 context sentences(design, population, supporting numbers)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326601
04HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, liraglutide lowered systolic blood pressure by a mean of 10.95 mm Hg.
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide lowered systolic blood pressure.
Peptide
Liraglutide
Outcome
DecreaseSystolic blood pressure change
Study
n = 29
Comparator
Control period without liraglutide
Outcome group
Blood pressure · Cardiovascular
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Measurements
Systolic blood pressure decrease
10.95 mm Hg
liraglutide
Source sentences
Summary
Liraglutide treatment led to a significant weight loss (mean 6.03 kg (95%CI: 5.22;6.84)) and decrease in systolic blood pressure (mean 10.95 mm Hg (95%CI: 4.60;17.30)).
2 context sentences(design, population, supporting numbers)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326602
05HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, liraglutide had no effect on left ventricular systolic function parameters.
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide did not change how well the heart pumps.
Peptide
Liraglutide
Outcome
No significant changeLeft ventricular systolic function
Study
n = 29
Comparator
Control period without liraglutide
Outcome group
Heart function · Cardiovascular
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no effects on symptoms measured by SAQ or parameters of left ventricular systolic as well as diastolic function
2 context sentences(design, population, supporting numbers)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326605
06HumanNon-randomized trialEfficacy outcome
In non-diabetic overweight women with coronary microvascular dysfunction, liraglutide had no effect on left ventricular diastolic function parameters.
In plain wordsIn overweight women without diabetes who had small-vessel heart disease, liraglutide did not change how well the heart relaxes and fills.
Peptide
Liraglutide
Outcome
No significant changeLeft ventricular diastolic function
Study
n = 29
Comparator
Control period without liraglutide
Outcome group
Heart function · Cardiovascular
Studied dose
aiming at 3 mg daily · 12 weeksAs given in this study (human).
Source sentences
Summary
There were no effects on symptoms measured by SAQ or parameters of left ventricular systolic as well as diastolic function
2 context sentences(design, population, supporting numbers)
Summary · context
We included 33 non-diabetic overweight women (BMI > 25) with CMD (Coronary flow velocity reserve (CFVR) ≤2.5), angina symptoms and no obstructive CAD, in an open-label proof-of-concept study.
Summary · context
The protocol included a control period of 5 weeks followed by an intervention period with liraglutide aiming at 3 mg daily for 12 weeks.
Report a problemFND-3077326606

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02602600

Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis

Eva Prescottn = 3319 Nov 2015 to 18 Apr 2017

Microvascular Angina

Trial page ClinicalTrials.govUpdated 11 Jul 2018

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.